Compare SKYH & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYH | DCTH |
|---|---|---|
| Founded | 2017 | 1988 |
| Country | United States | United States |
| Employees | 112 | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.2M | 372.5M |
| IPO Year | N/A | 2015 |
| Metric | SKYH | DCTH |
|---|---|---|
| Price | $10.24 | $12.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $13.13 | ★ $22.00 |
| AVG Volume (30 Days) | 177.1K | ★ 379.0K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $78.89 | $24.54 |
| Revenue Next Year | $73.15 | $33.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $8.12 |
| 52 Week High | $11.17 | $13.74 |
| Indicator | SKYH | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 44.31 |
| Support Level | $9.63 | $9.98 |
| Resistance Level | $10.47 | $12.48 |
| Average True Range (ATR) | 0.43 | 0.51 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 64.76 | 1.71 |
Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.